SCHEMBL6187488

SCHEMBL6187488

O=C1NC(=O)C(=Cc2ccc(-c3cccc(O)c3)cc2)S1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 3/20 0.76
PIK3CA P42336 1/20 0.65
PIK3CG P48736 1/20 0.65
TDP1 Q9NUW8 3/20 0.65
HPGD P15428 3/20 0.65
GSK3B P49841 1/20 0.65
RAB9A P51151 1/20 0.65
POLB P06746 2/20 0.62
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
PIM1 P11309 5/20 0.58
PIM2 Q9P1W9 5/20 0.58
PIM3 Q86V86 1/20 0.58
NAT1 P18440 2/20 0.57
CISD1 Q9NZ45 3/20 0.56
MAOA P21397 1/20 0.56
MAOB P27338 1/20 0.56
KDM4E B2RXH2 1/20 0.56
NSD2 O96028 1/20 0.56
GAA P10253 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6187486 1.00 AKR1B1 (0.76) AKR1B1PIK3CAPIK3CGTDP1HPGD
SCHEMBL18103006 0.89 NAT1 (0.74) AKR1B1PIK3CAPIK3CGRAB9AMEN1
SCHEMBL12259747 0.87 AKR1B1 (1.00) AKR1B1TDP1HPGDGSK3BRAB9A
SCHEMBL1248782 0.83 PIM1 (0.83) AKR1B1PIK3CGTDP1HPGDGSK3B
SCHEMBL1248780 0.83 PIM1 (0.83) AKR1B1PIK3CGTDP1HPGDGSK3B
SCHEMBL12891790 0.83 PIM1 (0.83) AKR1B1PIK3CGTDP1HPGDGSK3B
SCHEMBL6187852 0.83 AKR1B1 (0.76) AKR1B1TDP1HPGDGSK3BRAB9A
SCHEMBL6187848 0.83 AKR1B1 (0.76) AKR1B1TDP1HPGDGSK3BRAB9A
SCHEMBL6202184 0.82 PIM1 (0.76) AKR1B1HPGDGSK3BPOLBMEN1
SCHEMBL6184899 0.82 PIK3CG (0.67) AKR1B1PIK3CGTDP1HPGDGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed
EP-1309575-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS Galderma Research & Development (FR) 2003-05-14 EP disclosed
WO-2002012210-A9 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2002-04-18 WO disclosed
WO-2002012210-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD AKR1B1 347/4885PIK3CA 454/4885PIK3CG 1138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.